At the end of 2005, six European countries had implemented public immunisation campaigns with serogroup C conjugate vaccines to date and all had experienced substantial declines in the incidence of serogroup C disease. A quadrivalent ACWY meningococcal vaccine is in use in the USA, but serogroup A is extremely rare in Europe and serogroups Y and W-135 are infrequent causes of disease. This paper outlines recommendations about the use of conjugate vaccines in Europe, based on the experience with MCC vaccines so far.
|Translated title of the contribution||Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines|
|Pages (from-to)||101 - 107|
|Number of pages||7|
|Journal||FEMS Microbiology Reviews|
|Publication status||Published - Jan 2007|